[Skip to Content]
[Skip to Content Landing]

Efficacy of Tramadol Extended-Release for Opioid WithdrawalA Randomized Clinical Trial

Educational Objective To evaluate whether tramadol hydrochloride extended-release, an approved analgesic with opioid and nonopioid mechanisms of action and low abuse potential, is effective for use in supervised withdrawal settings.
1 Credit CME
Key Points

Question  What is the relative efficacy of tramadol hydrochloride extended-release vs clonidine or buprenorphine hydrochloride in supervised opioid withdrawal settings?

Findings  This randomized clinical trial shows that tramadol extended-release suppressed withdrawal more than clonidine and comparably to buprenorphine during a double-blind taper and did not produce a delayed onset of opioid withdrawal after the taper.

Meaning  Tramadol extended-release is a Schedule IV medication that is available generically and can suppress withdrawal comparably to buprenorphine and superior to clonidine, suggesting that tramadol extended-release may have clinical value for the indication of opioid withdrawal suppression.

Abstract

Importance  Opioid use disorder (OUD) is a significant public health problem. Supervised withdrawal (ie, detoxification) from opioids using clonidine or buprenorphine hydrochloride is a widely used treatment.

Objective  To evaluate whether tramadol hydrochloride extended-release (ER), an approved analgesic with opioid and nonopioid mechanisms of action and low abuse potential, is effective for use in supervised withdrawal settings.

Design, Setting, and Participants  A randomized clinical trial was conducted in a residential research setting with 103 participants with OUD. Participants’ treatment was stabilized with morphine, 30 mg, administered subcutaneously 4 times daily. A 7-day taper using clonidine (n = 36), tramadol ER (n = 36), or buprenorphine (n = 31) was then instituted, and patients were crossed-over to double-blind placebo during a post-taper period. The study was conducted from October 25, 2010, to June 23, 2015.

Main Outcomes and Measures  Retention, withdrawal symptom management, concomitant medication utilization, and naltrexone induction. Results were analyzed over time and using area under the curve for the intention-to-treat and completer groups.

Results  Of the 103 participants, 88 (85.4%) were men and 43 (41.7%) were white; mean (SD) age was 28.9 (10.4) years. Buprenorphine participants (28 [90.3%]) were significantly more likely to be retained at the end of the taper compared with clonidine participants (22 [61.1%]); tramadol ER retention was intermediate and did not differ significantly from that of the other groups (26 [72.2%]; χ2 = 8.5, P = .01). Time-course analyses of withdrawal revealed significant effects of phase (taper, post taper) for the Clinical Opiate Withdrawal Scale (COWS) score (taper mean, 5.19 [SE, .26]; post-taper mean, 3.97 [SE, .23]; F2,170 = 3.6, P = .03) and Subjective Opiate Withdrawal Scale (SOWS) score (taper mean,8.81 [SE, .40]; post-taper mean, 4.14 [SE, .30]; F2,170 = 15.7, P < .001), but no group effects or group × phase interactions. Analyses of area under the curve of SOWS total scores showed significant reductions (F2,159 = 17.7, P < .001) in withdrawal severity between the taper and post-taper periods for clonidine (taper mean, 13.1; post-taper mean, 3.2; P < .001) and tramadol ER (taper mean, 7.4; post-taper mean, 2.8; P = .03), but not buprenorphine (taper mean, 6.4; post-taper mean, 7.4). Use of concomitant medication increased significantly (F2,159 = 30.7,  P < .001) from stabilization to taper in the clonidine (stabilization mean, 0.64 [SE, .05]; taper mean, 1.54 [SE, .10]; P < .001) and tramadol ER (stabilization mean, 0.53 [SE, .05]; taper mean, 1.19 [SE, .09]; P = .003) groups and from stabilization to post taper in the buprenorphine group (stabilization mean, 0.46 [SE, .05] post-taper mean, 1.17 [SE, .09]; P = .006), suggesting higher withdrawal for those groups during those periods. Naltrexone initiation was voluntary and the percentage of participants choosing naltrexone therapy within the clonidine (8 [22.2%]), tramadol ER (7 [19.4%]), or buprenorphine (3 [9.7%]) groups did not differ significantly (χ2 = 2.5, P = .29).

Conclusions and Relevance  The results of this trial suggest that tramadol ER is more effective than clonidine and comparable to buprenorphine in reducing opioid withdrawal symptoms during a residential tapering program. Data support further examination of tramadol ER as a method to manage opioid withdrawal symptoms.

Trial Registration  Clinicaltrials.gov Identifier: NCT01188421

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: May 16, 2017.

Corresponding Author: Kelly E. Dunn, PhD, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr, Baltimore, MD 21224 (kdunn9@jhmi.edu).

Correction: This article was corrected on September 6, 2017, for errors in the abstract and an error in the discussion section; this article was corrected on February 14, 2018, to fix an error in the Key Points and the Conclusions of the article.

Published Online: July 12, 2017. doi:10.1001/jamapsychiatry.2017.1838

Author Contributions: Dr Dunn had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Strain.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Dunn, Strain.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Dunn, Strain.

Obtained funding: Strain.

Administrative, technical, or material support: All authors.

Supervision: Tompkins, Strain.

Conflict of Interest Disclosures: Dr Strain has been a paid consultant for Indivior Pharmaceuticals and is a paid advisory board member for the Egalet Corporation, The Oak Group, and Pinney Associates. Dr Tompkins has received medication supplies from Indivior Inc for an investigator-initiated research protocol; has been a paid consultant with Astra-Zeneca and Theravance; and is site principal investigator for a multisite clinical trial funded by Alkermes. No other disclosures are reported.

Funding/Support: This study was funded by National Institute on Drug Abuse grant R01DA-018125 (Dr Strain), with additional salary support provided by grants R01DA035246, R01DA040644 (Dr Dunn), K23DA029609 (Dr Tompkins), and T32DA007209 (Dr Bigelow). Buprenorphine sublingual tablets and placebo tablets were provided by an unrestricted, unsolicited investigator-initiated grant from Reckitt Benckiser Pharmaceuticals.

Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Reckitt Benckiser Pharmaceuticals had no role in the study design, collection, analysis, and interpretation of data or in the writing of the manuscript, but reviewed the report for scientific accuracy.

Additional Contributions: Paul Nuzzo, MS (University of Kentucky), helped with data analyses and Jessica Sides, BA, and Hye Jeong Han, BA (conducted at The Johns Hopkins University), managed daily study activities; they received financial compensation for these contributions. The Behavioral Pharmacology Research Unit and Bayview Clinical Research Unit staff provided many varied and valuable contributions.

References
1.
Birnbaum  HG, White  AG, Schiller  M, Waldman  T, Cleveland  JM, Roland  CL.  Societal costs of prescription opioid abuse, dependence, and misuse in the United States.  Pain Med. 2011;12(4):657-667.PubMedGoogle ScholarCrossref
2.
Strassels  SA.  Economic burden of prescription opioid misuse and abuse.  J Manag Care Pharm. 2009;15(7):556-562.PubMedGoogle Scholar
3.
CDC Wonder. Compressed Mortality File. http://wonder.cdc.gov/mortsql.html. Updated 2014. Accessed June 1, 2017.
4.
Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set 2002-2012. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Department of Health and Human Services; 2014. HHS Publication No. (SMA) 14-4850. https://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf.Accessed June 7, 2017.
5.
Bailey  GL, Herman  DS, Stein  MD.  Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification.  J Subst Abuse Treat. 2013;45(3):302-305.PubMedGoogle ScholarCrossref
6.
Northrup  TF, Stotts  AL, Green  C,  et al.  Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.  Addict Behav. 2015;41:20-28.PubMedGoogle ScholarCrossref
7.
Strobbe  S, Brower  KJ, Galen  LW.  Predicting completion of outpatient opioid detoxification with clonidine.  Am J Addict. 2003;12(3):260-269.PubMedGoogle ScholarCrossref
8.
Gowing  L, Farrell  M, Ali  R, White  JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016;(5):CD002024. Medline: 19370574
9.
Meader  N.  A comparison of methadone, buprenorphine and alpha2 adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.  Drug Alcohol Depend. 2010;108(1-2):110-114.PubMedGoogle ScholarCrossref
10.
Jasinski  DR, Pevnick  JS, Griffith  JD.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.  Arch Gen Psychiatry. 1978;35(4):501-516.PubMedGoogle ScholarCrossref
11.
Dunn  KE, Sigmon  SC, Strain  EC, Heil  SH, Higgins  ST.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.  Drug Alcohol Depend. 2011;119(1-2):1-9.PubMedGoogle ScholarCrossref
12.
Nielsen  S, Larance  B, Degenhardt  L, Gowing  L, Kehler  C, Lintzeris  N.  Opioid agonist treatment for pharmaceutical opioid dependent people.  Cochrane Database Syst Rev. 2016;(5):CD011117.PubMedGoogle Scholar
13.
Hutchinson  E, Catlin  M, Andrilla  CH, Baldwin  LM, Rosenblatt  RA.  Barriers to primary care physicians prescribing buprenorphine.  Ann Fam Med. 2014;12(2):128-133.PubMedGoogle ScholarCrossref
14.
Molfenter  T, Sherbeck  C, Zehner  M,  et al.  Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.  Subst Abuse Treat Prev Policy. 2015;10(1):13.PubMedGoogle ScholarCrossref
15.
Schuman-Olivier  Z, Connery  H, Griffin  ML,  et al.  Clinician beliefs and attitudes about buprenorphine/naloxone diversion.  Am J Addict. 2013;22(6):574-580.PubMedGoogle ScholarCrossref
16.
Gillen  C, Haurand  M, Kobelt  DJ, Wnendt  S.  Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor.  Naunyn Schmiedebergs Arch Pharmacol. 2000;362(2):116-121.PubMedGoogle ScholarCrossref
17.
Hennies  HH, Friderichs  E, Schneider  J.  Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids.  Arzneimittelforschung. 1988;38(7):877-880.PubMedGoogle Scholar
18.
Raffa  RB, Friderichs  E, Reimann  W, Shank  RP, Codd  EE, Vaught  JL.  Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic.  J Pharmacol Exp Ther. 1992;260(1):275-285.PubMedGoogle Scholar
19.
Gibson  TP.  Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl.  Am J Med. 1996;101(1A):47S-53S.PubMedGoogle ScholarCrossref
20.
O’Connor  EC, Mead  AN.  Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans.  Pharmacol Biochem Behav. 2010;96(3):279-286.PubMedGoogle ScholarCrossref
21.
Preston  KL, Jasinski  DR, Testa  M.  Abuse potential and pharmacological comparison of tramadol and morphine.  Drug Alcohol Depend. 1991;27(1):7-17.PubMedGoogle ScholarCrossref
22.
Lofwall  MR, Walsh  SL, Bigelow  GE, Strain  EC.  Modest opioid withdrawal suppression efficacy of oral tramadol in humans.  Psychopharmacology (Berl). 2007;194(3):381-393.PubMedGoogle ScholarCrossref
23.
Lofwall  MR, Babalonis  S, Nuzzo  PA, Siegel  A, Campbell  C, Walsh  SL.  Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.  Drug Alcohol Depend. 2013;133(1):188-197.PubMedGoogle ScholarCrossref
24.
Sobey  PW, Parran  TV  Jr, Grey  SF, Adelman  CL, Yu  J.  The use of tramadol for acute heroin withdrawal: a comparison to clonidine.  J Addict Dis. 2003;22(4):13-25.PubMedGoogle ScholarCrossref
25.
Chattopadhyay  S, Singh  OP, Bhattacharyya  A, Sen  S, Roy  P, Debnath  S.  Tramadol versus clonidine in management of heroin withdrawal.  Asian J Psychiatr. 2010;3(4):237-239.PubMedGoogle ScholarCrossref
26.
Tamaskar  R, Parran  TV  Jr, Heggi  A, Brateanu  A, Rabb  M, Yu  J.  Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study.  J Addict Dis. 2003;22(4):5-12.PubMedGoogle ScholarCrossref
27.
Threlkeld  M, Parran  TV, Adelman  CA, Grey  SF, Yu  J.  Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.  Am J Addict. 2006;15(2):186-191.PubMedGoogle ScholarCrossref
28.
Zarghami  M, Masoum  B, Shiran  MR.  Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial.  J Addict Dis. 2012;31(2):112-117.PubMedGoogle ScholarCrossref
29.
Ziaaddini  H, Ziaaddini  A, Asghari  N, Nakhaee  N, Eslami  M.  Trial of tramadol plus gabapentin for opioid detoxification.  Iran Red Crescent Med J. 2014;17(1):e18202.PubMedGoogle ScholarCrossref
30.
Wesson  DR, Ling  W.  The Clinical Opiate Withdrawal Scale (COWS).  J Psychoactive Drugs. 2003;35(2):253-259.PubMedGoogle ScholarCrossref
31.
Gan  SH, Ismail  R, Wan Adnan  WA, Zulmi  W.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.  Mol Diagn Ther. 2007;11(3):171-181.PubMedGoogle ScholarCrossref
32.
Lassen  D, Damkier  P, Brøsen  K.  The pharmacogenetics of tramadol.  Clin Pharmacokinet. 2015;54(8):825-836.PubMedGoogle ScholarCrossref
33.
Handelsman  L, Cochrane  KJ, Aronson  MJ, Ness  R, Rubinstein  KJ, Kanof  PD.  Two new rating scales for opiate withdrawal.  Am J Drug Alcohol Abuse. 1987;13(3):293-308.PubMedGoogle ScholarCrossref
34.
Morley  KI, Ferris  JA, Winstock  AR, Lynskey  MT.  Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data.  Pain. 2017;158(6):1138-1144.PubMedGoogle ScholarCrossref
35.
Sigmon  SC, Dunn  KE, Badger  GJ, Heil  SH, Higgins  ST.  Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.  Addict Behav. 2009;34(3):304-311.PubMedGoogle ScholarCrossref
36.
Fiellin  DA, Schottenfeld  RS, Cutter  CJ, Moore  BA, Barry  DT, O’Connor  PG.  Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.  JAMA Intern Med. 2014;174(12):1947-1954.PubMedGoogle ScholarCrossref
37.
Ravndal  E, Amundsen  EJ.  Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study.  Drug Alcohol Depend. 2010;108(1-2):65-69.PubMedGoogle ScholarCrossref
38.
Kosten  TR, Rounsaville  BJ, Kleber  HD.  Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts.  Am J Drug Alcohol Abuse. 1985;11(1-2):1-10.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Topics
State Requirements